ALK and adenocarcinoma: Therefore, this ALK+ LCNEC patient demonstrates the adverse impact of LCNEC histology and how this can interact with molecular properties to shape an intermediate OS of 37 mo (Fig. 1) versus >5 yr in median for ALK+ adenocarcinomas, and 12 mo in median for other LCNEC (Mok et al. 2020; Fisch et al. 2021).